CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.
January 13th 2025
Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.
Despite Her Unique 'Previvorship' Experience, One Woman Shares Universal Truths
May 22nd 2019"We hope that this array of articles, while offering comprehensive information about cutting-edge treatments, will also serve as a reminder of the shared experience of those in the cancer community and the sense of connection it can bring," said Chairman and CEO, Mike Hennessy, Sr.
Identifying Genetic Similarities in Tumors May Shed Light on Spread of Ovarian Cancer
March 26th 2019Researchers define the genetic characteristics of ovarian tumors-- information that could lead to new opportunities for personalized therapy and may explain why screening programs for the disease haven’t been successful.
Ovarian Cancer Screening Tool Should be a Top Research Priority
March 21st 2019Did we bring this scary, painful, financially draining monster into our lives by eating too many cookies and not doing enough jumping jacks? We need a reliable diagnostic screening tool for ovarian cancer and we need it now.
Triplet Combo Yields Durable Responses in Recurrent Epithelial Ovarian Cancer
March 19th 2019Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.
Initial PARP Inhibitor Use for Ovarian Cancer May Not Lead to Resistance in Secondary Use
March 18th 2019Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.
Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy
March 18th 2019Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.
Zejula Maintenance Therapy Extends Symptom-Free Survival in Recurrent Ovarian Cancer
March 17th 2019Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.